Section 32

Founded:

2017

Investments:

Exits:

About Section 32

Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.

Portfolio companies:

Primer,Aspen Neuroscience,Embark,MOMA Therapeutics,Gretel,C2i Genomics,Celsius Therapeutics,Arbor Biotechnologies,Neocis,WithMe Health,Mekonos,Syllable,Character Biosciences,Culture Biosciences,Satellite Bio,Current Health,Wise Systems,Verge Genomics,Vineti,Miroculus,ROME Therapeutics,TwinStrand Biosciences,Exai Bio,MedArrive

Fund type:

Venture Fund

Investment stage:

Pre-Seed

Seed

Series A

Investment focus:

Big Data & Analytics

Artificial Intelligence & Machine Learning (AI/ML)

Developer Tools

BioTech

PetTech

Software

Robotics

HR Tech

InsurTech

EdTech

CloudTech

Enterprise

HQ-Country:

United States

City:

San Diego

Go to website